FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
出版年份 2013 全文链接
标题
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
作者
关键词
FOLFIRI, Bevacizumab, Second line, Colorectal cancer
出版物
MEDICAL ONCOLOGY
Volume 30, Issue 1, Pages -
出版商
Springer Nature
发表日期
2013-02-11
DOI
10.1007/s12032-013-0486-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer
- (2012) Ramazan Yildiz et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Verification Trials of mFOLFIRI and Sequential Irinotecan + Bevacizumab as First- or Second-Line Therapies for Metastatic Colorectal Cancer in Japanese Patients
- (2012) Shunsuke Kato et al. ONCOLOGY
- Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
- (2011) Antoine Brouquet et al. CANCER
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
- (2011) Jaafar Bennouna et al. Clinical Colorectal Cancer
- Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
- (2011) Fausto Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study
- (2011) S. Sogabe et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial
- (2011) Michel Ducreux et al. LANCET ONCOLOGY
- Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)
- (2011) Toshikazu Moriwaki et al. MEDICAL ONCOLOGY
- Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
- (2011) Mitsukuni Suenaga et al. SURGERY TODAY
- Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
- (2009) F.-C. Bidard et al. ANNALS OF ONCOLOGY
- Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
- (2009) Astrid Lièvre et al. BMC CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started